642 related articles for article (PubMed ID: 25680936)
1. The value of urodynamic tools to guide patient selection in sacral neuromodulation.
Drossaerts J; Rademakers K; van Koeveringe G; Van Kerrebroeck P
World J Urol; 2015 Nov; 33(11):1889-95. PubMed ID: 25680936
[TBL] [Abstract][Full Text] [Related]
2. The Value of Ambulatory Urodynamics in the Evaluation of Treatment Effect of Sacral Neuromodulation.
Drossaerts J; Rademakers KLJ; Rahnama'i SM; Marcelissen T; Van Kerrebroeck P; van Koeveringe G
Urol Int; 2019; 102(3):299-305. PubMed ID: 30612126
[TBL] [Abstract][Full Text] [Related]
3. PNE versus 1st stage tined lead procedure: a direct comparison to select the most sensitive test method to identify patients suitable for sacral neuromodulation therapy.
Leong RK; De Wachter SG; Nieman FH; de Bie RA; van Kerrebroeck PE
Neurourol Urodyn; 2011 Sep; 30(7):1249-52. PubMed ID: 21404317
[TBL] [Abstract][Full Text] [Related]
4. Acute effect of sacral neuromodulation for treatment of detrusor overactivity on urodynamic parameters.
Groenendijk IM; Groen J; Scheepe JR; Blok BFM
Neurourol Urodyn; 2020 Feb; 39(2):695-701. PubMed ID: 31804759
[TBL] [Abstract][Full Text] [Related]
5. [Sacral neuromodulation in urology. The emperor's new clothes or effective high-tech medicine?].
Hoda MR; Fornara P
Urologe A; 2010 Oct; 49(10):1254-9. PubMed ID: 20859609
[TBL] [Abstract][Full Text] [Related]
6. Sacral Nerve Stimulation for Pediatric Lower Urinary Tract Dysfunction: Development of a Standardized Pathway with Objective Urodynamic Outcomes.
Schober MS; Sulkowski JP; Lu PL; Minneci PC; Deans KJ; Teich S; Alpert SA
J Urol; 2015 Dec; 194(6):1721-6. PubMed ID: 26141849
[TBL] [Abstract][Full Text] [Related]
7. Urodynamic evaluation of sacral neuromodulation for urge urinary incontinence.
Groenendijk PM; Lycklama à Nyeholt AA; Heesakkers JP; van Kerrebroeck PE; Hassouna MM; Gajewski JB; Cappellano F; Siegel SW; Fall M; Dijkema HE; Jonas U; van den Hombergh U;
BJU Int; 2008 Feb; 101(3):325-9. PubMed ID: 18070199
[TBL] [Abstract][Full Text] [Related]
8. The Impact of Duration of Complaints on Successful Outcome of Sacral Neuromodulation.
Jairam R; Drossaerts J; van Koeveringe G; van Kerrebroeck P
Urol Int; 2017; 99(1):51-55. PubMed ID: 28478446
[TBL] [Abstract][Full Text] [Related]
9. Screening for depression and anxiety in patients with storage or voiding dysfunction: A retrospective cohort study predicting outcome of sacral neuromodulation.
Drossaerts J; Vrijens D; Leue C; Schilders I; Van Kerrebroeck P; van Koeveringe G
Neurourol Urodyn; 2016 Nov; 35(8):1011-1016. PubMed ID: 26351817
[TBL] [Abstract][Full Text] [Related]
10. The effect of sacral neuromodulation on pudendal nerve function and female sexual function.
Parnell BA; Howard JF; Geller EJ
Neurourol Urodyn; 2015 Jun; 34(5):456-60. PubMed ID: 24615871
[TBL] [Abstract][Full Text] [Related]
11. Urodynamic findings during the filling phase in neurogenic bladder patients with or without vesicoureteral reflux who have undergone sacral neuromodulation.
Chen G; Liao L; Wang Y; Ying X
Neurourol Urodyn; 2020 Jun; 39(5):1410-1416. PubMed ID: 32282088
[TBL] [Abstract][Full Text] [Related]
12. Sacral neuromodulation for neurogenic non-obstructive urinary retention in incomplete spinal cord patients: a ten-year follow-up single-centre experience.
Lombardi G; Musco S; Celso M; Del Corso F; Del Popolo G
Spinal Cord; 2014 Mar; 52(3):241-5. PubMed ID: 24394604
[TBL] [Abstract][Full Text] [Related]
13. Onset of Action of Sacral Neuromodulation in Lower Urinary Tract Dysfunction-What is the Optimal Duration of Test Stimulation?
Jairam R; Drossaerts J; Marcelissen T; van Koeveringe G; van Kerrebroeck P
J Urol; 2018 Jun; 199(6):1584-1590. PubMed ID: 29291416
[TBL] [Abstract][Full Text] [Related]
14. [Sacral neuromodulation in under- and overactive detrusor-quo vadis? : Principles and developments].
Girtner F; Burger M; Mayr R
Urologe A; 2019 Jun; 58(6):634-639. PubMed ID: 31139864
[TBL] [Abstract][Full Text] [Related]
15. Long-term follow-up of sacral neuromodulation for lower urinary tract dysfunction.
Peeters K; Sahai A; De Ridder D; Van Der Aa F
BJU Int; 2014 May; 113(5):789-94. PubMed ID: 24238278
[TBL] [Abstract][Full Text] [Related]
16. Sacral neuromodulation in diabetic patients: success and complications in the treatment of voiding dysfunction.
Daniels DH; Powell CR; Braasch MR; Kreder KJ
Neurourol Urodyn; 2010 Apr; 29(4):578-81. PubMed ID: 19760757
[TBL] [Abstract][Full Text] [Related]
17. Psychological and psychiatric factors as predictors for success in sacral neuromodulation treatment.
Marcelissen TA; Leong RK; Nieman FH; van Lankveld JJ; van Kerrebroeck PE; de Wachter SG
BJU Int; 2011 Dec; 108(11):1834-8. PubMed ID: 21810157
[TBL] [Abstract][Full Text] [Related]
18. Prediction of sacral neuromodulation treatment success in men with impaired bladder emptying-time for a new diagnostic approach.
Rademakers KL; Drossaerts JM; van Kerrebroeck PE; Oelke M; van Koeveringe GA
Neurourol Urodyn; 2017 Mar; 36(3):808-810. PubMed ID: 27062496
[TBL] [Abstract][Full Text] [Related]
19. Optimizing the duration of assessment of stage-1 sacral neuromodulation in nonobstructive chronic urinary retention.
Elneil S; Abtahi B; Helal M; Digesu A; Gonzales G
Neuromodulation; 2014 Jan; 17(1):66-70; discussion 70-1. PubMed ID: 23601054
[TBL] [Abstract][Full Text] [Related]
20. Ambulatory urodynamic studies (UDS) in children using a Bluetooth-enabled device.
Deshpande AV; Craig JC; Caldwell PH; Smith GH
BJU Int; 2012 Dec; 110 Suppl 4():38-45. PubMed ID: 23194124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
